Literature DB >> 30471294

Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus.

Shu-Hui Chuang1, Doodipala Samba Reddy2.   

Abstract

Zinc is an abundant trace metal in the hippocampus nerve terminals. Previous studies demonstrate the ability of zinc to selectively block neurosteroid-sensitive, extrasynaptic GABA-A receptors in the hippocampus (Carver et al, 2016). Here we report that zinc prevents the seizure protective effects of the synthetic neurosteroid ganaxolone (GX) in an experimental model of epilepsy. GABA-gated and tonic currents were recorded from dissociated dentate gyrus granule cells (DGGCs), CA1 pyramidal cells (CA1PCs), and hippocampal slices from adult mice. Antiseizure effects of GX and the reversal of these effects by zinc were evaluated in fully-kindled mice expressing generalized (stage 5) seizures. In electrophysiological studies, zinc blocked the GABA-evoked and GX-potentiated GABA-gated chloride currents in DGGCs and CA1PCs in a concentration-dependent fashion similar to the competitive GABA-A receptor antagonists bicuculline and gabazine. Zinc completely blocked GX potentiation of extrasynaptic tonic currents, but not synaptic phasic currents. In hippocampus kindling studies, systemic administration of GX produced a dose-dependent suppression of behavioral and electrographic seizures in fully-kindled mice with complete seizure protection at the 10 mg/kg dose. However, the antiseizure effects of GX were significantly prevented by intrahippocampal administration of zinc (ED50, 150 μM). The zinc antagonistic response was reversible as animals responded normally to GX administration 24 h post-zinc blockade. These results demonstrate that zinc reduces the antiseizure effects of GX by selectively blocking extrasynaptic δGABA-A receptors in the hippocampus. These pharmacodynamic interactions have clinical implications in neurosteroid therapy for brain conditions associated with zinc fluctuations.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GABA-A receptors; Ganaxolone; Hippocampus; Seizures; Tonic inhibition; Zinc

Mesh:

Substances:

Year:  2018        PMID: 30471294      PMCID: PMC6424640          DOI: 10.1016/j.neuropharm.2018.11.031

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  84 in total

Review 1.  Neurobiology of epileptogenesis in the temporal lobe.

Authors:  L Jutila; A Immonen; K Partanen; J Partanen; E Mervaala; A Ylinen; I Alafuzoff; L Paljärvi; K Karkola; M Vapalahti; A Pitkänen
Journal:  Adv Tech Stand Neurosurg       Date:  2002

2.  Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy.

Authors:  D S Reddy; M A Rogawski
Journal:  Epilepsia       Date:  2001-03       Impact factor: 5.864

Review 3.  The neurobiology of zinc in health and disease.

Authors:  Christopher J Frederickson; Jae-Young Koh; Ashley I Bush
Journal:  Nat Rev Neurosci       Date:  2005-06       Impact factor: 34.870

4.  Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?

Authors:  Joseph Glykys; Edward O Mann; Istvan Mody
Journal:  J Neurosci       Date:  2008-02-06       Impact factor: 6.167

5.  Antiseizure Activity of Midazolam in Mice Lacking δ-Subunit Extrasynaptic GABA(A) Receptors.

Authors:  Sandesh D Reddy; Iyan Younus; Bryan L Clossen; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2015-03-17       Impact factor: 4.030

6.  Zinc inhibition of gamma-aminobutyric acid(A) receptor function is decreased in the cerebral cortex during pilocarpine-induced status epilepticus.

Authors:  P K Banerjee; R W Olsen; O C Snead
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

7.  Micromolar concentrations of Zn2+ antagonize NMDA and GABA responses of hippocampal neurons.

Authors:  G L Westbrook; M L Mayer
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

8.  The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.

Authors:  Sien Braat; Charlotte D'Hulst; Inge Heulens; Silvia De Rubeis; Edwin Mientjes; David L Nelson; Rob Willemsen; Claudia Bagni; Debby Van Dam; Peter P De Deyn; R Frank Kooy
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself.

Authors:  D S Reddy; M A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

10.  Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model.

Authors:  E H Buhl; T S Otis; I Mody
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

View more
  5 in total

1.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

Review 2.  Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

Authors:  Victoria M Golub; Doodipala Samba Reddy
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

Review 3.  Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.

Authors:  Doodipala Samba Reddy
Journal:  J Neuroendocrinol       Date:  2021-09-10       Impact factor: 3.870

4.  Comparison of Serum Trace Nutrient Concentrations in Epileptics Compared to Healthy Dogs.

Authors:  Samantha Vitale; Devon Wallis Hague; Kari Foss; Maria Cattai de Godoy; Laura E Selmic
Journal:  Front Vet Sci       Date:  2019-12-19

5.  Crosstalk of copper and zinc in the pathogenesis of vascular dementia.

Authors:  Masahiro Kawahara; Ken-Ichiro Tanaka; Midori Kato-Negishi
Journal:  J Clin Biochem Nutr       Date:  2022-07-01       Impact factor: 3.179

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.